Literature DB >> 22173295

Brain imaging in the study of Alzheimer's disease.

Eric M Reiman1, William J Jagust.   

Abstract

Over the last 20 years, there has been extraordinary progress in brain imaging research and its application to the study of Alzheimer's disease (AD). Brain imaging researchers have contributed to the scientific understanding, early detection and tracking of AD. They have set the stage for imaging techniques to play growing roles in the clinical setting, the evaluation of disease-modifying treatments, and the identification of demonstrably effective prevention therapies. They have developed ground-breaking methods, including positron emission tomography (PET) ligands to measure fibrillar amyloid-β (Aβ) deposition, new magnetic resonance imaging (MRI) pulse sequences, and powerful image analysis techniques, to help in these endeavors. Additional work is needed to develop even more powerful imaging methods, to further clarify the relationship and time course of Aβ and other disease processes in the predisposition to AD, to establish the role of brain imaging methods in the clinical setting, and to provide the scientific means and regulatory approval pathway needed to evaluate the range of promising disease-modifying and prevention therapies as quickly as possible. Twenty years from now, AD may not yet be a distant memory, but the best is yet to come.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22173295      PMCID: PMC3351556          DOI: 10.1016/j.neuroimage.2011.11.075

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  177 in total

1.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Authors:  Victor L Villemagne; Kerryn E Pike; Gaël Chételat; Kathryn A Ellis; Rachel S Mulligan; Pierrick Bourgeat; Uwe Ackermann; Gareth Jones; Cassandra Szoeke; Olivier Salvado; Ralph Martins; Graeme O'Keefe; Chester A Mathis; William E Klunk; David Ames; Colin L Masters; Christopher C Rowe
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

2.  Anatomy of language impairments in primary progressive aphasia.

Authors:  Emily Rogalski; Derin Cobia; Theresa M Harrison; Christina Wieneke; Cynthia K Thompson; Sandra Weintraub; M-Marsel Mesulam
Journal:  J Neurosci       Date:  2011-03-02       Impact factor: 6.167

3.  Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis.

Authors:  Kim A Celone; Vince D Calhoun; Bradford C Dickerson; Alireza Atri; Elizabeth F Chua; Saul L Miller; Kristina DePeau; Doreen M Rentz; Dennis J Selkoe; Deborah Blacker; Marilyn S Albert; Reisa A Sperling
Journal:  J Neurosci       Date:  2006-10-04       Impact factor: 6.167

4.  Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment.

Authors:  A Nordberg; H Lundqvist; P Hartvig; J Andersson; M Johansson; E Hellstrŏm-Lindahi; B Långström
Journal:  Dement Geriatr Cogn Disord       Date:  1997 Mar-Apr       Impact factor: 2.959

5.  Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain.

Authors:  Seok Rye Choi; Geoff Golding; Zhiping Zhuang; Wei Zhang; Nathaniel Lim; Franz Hefti; Tyler E Benedum; Michael R Kilbourn; Daniel Skovronsky; Hank F Kung
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

6.  Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.

Authors:  Natalie Nelissen; Koen Van Laere; Lennart Thurfjell; Rikard Owenius; Mathieu Vandenbulcke; Michel Koole; Guy Bormans; David J Brooks; Rik Vandenberghe
Journal:  J Nucl Med       Date:  2009-07-17       Impact factor: 10.057

7.  Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study.

Authors:  Peter P Zandi; James C Anthony; Ara S Khachaturian; Stephanie V Stone; Deborah Gustafson; JoAnn T Tschanz; Maria C Norton; Kathleen A Welsh-Bohmer; John C S Breitner
Journal:  Arch Neurol       Date:  2004-01

8.  Amyloid deposition is associated with impaired default network function in older persons without dementia.

Authors:  Reisa A Sperling; Peter S Laviolette; Kelly O'Keefe; Jacqueline O'Brien; Dorene M Rentz; Maija Pihlajamaki; Gad Marshall; Bradley T Hyman; Dennis J Selkoe; Trey Hedden; Randy L Buckner; J Alex Becker; Keith A Johnson
Journal:  Neuron       Date:  2009-07-30       Impact factor: 17.173

9.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.

Authors:  Norman L Foster; Judith L Heidebrink; Christopher M Clark; William J Jagust; Steven E Arnold; Nancy R Barbas; Charles S DeCarli; R Scott Turner; Robert A Koeppe; Roger Higdon; Satoshi Minoshima
Journal:  Brain       Date:  2007-08-18       Impact factor: 13.501

10.  Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees.

Authors:  William E Klunk; Julie C Price; Chester A Mathis; Nicholas D Tsopelas; Brian J Lopresti; Scott K Ziolko; Wenzhu Bi; Jessica A Hoge; Ann D Cohen; Milos D Ikonomovic; Judith A Saxton; Beth E Snitz; Daniel A Pollen; Majaz Moonis; Carol F Lippa; Joan M Swearer; Keith A Johnson; Dorene M Rentz; Alan J Fischman; Howard J Aizenstein; Steven T DeKosky
Journal:  J Neurosci       Date:  2007-06-06       Impact factor: 6.167

View more
  35 in total

1.  Progressive brain atrophy in chronically infected and treated HIV+ individuals.

Authors:  Talia M Nir; Neda Jahanshad; Christopher R K Ching; Ronald A Cohen; Jaroslaw Harezlak; Giovanni Schifitto; Hei Y Lam; Xue Hua; Jianhui Zhong; Tong Zhu; Michael J Taylor; Thomas B Campbell; Eric S Daar; Elyse J Singer; Jeffry R Alger; Paul M Thompson; Bradford A Navia
Journal:  J Neurovirol       Date:  2019-02-14       Impact factor: 2.643

2.  An MRI-based index to measure the severity of Alzheimer's disease-like structural pattern in subjects with mild cognitive impairment.

Authors:  G Spulber; A Simmons; J-S Muehlboeck; P Mecocci; B Vellas; M Tsolaki; I Kłoszewska; H Soininen; C Spenger; S Lovestone; L-O Wahlund; E Westman
Journal:  J Intern Med       Date:  2013-01-30       Impact factor: 8.989

Review 3.  Modeling of PET data in CNS drug discovery and development.

Authors:  Katarina Varnäs; Andrea Varrone; Lars Farde
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-05-10       Impact factor: 2.745

Review 4.  Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease.

Authors:  David A Bennett; Lei Yu; Philip L De Jager
Journal:  Biochem Pharmacol       Date:  2014-02-06       Impact factor: 5.858

5.  Joint Multi-Modal Longitudinal Regression and Classification for Alzheimer's Disease Prediction.

Authors:  Lodewijk Brand; Kai Nichols; Hua Wang; Li Shen; Heng Huang
Journal:  IEEE Trans Med Imaging       Date:  2019-12-13       Impact factor: 10.048

Review 6.  Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.

Authors:  Kaj Blennow; Harald Hampel; Henrik Zetterberg
Journal:  Neuropsychopharmacology       Date:  2013-06-25       Impact factor: 7.853

7.  Higher homocysteine associated with thinner cortical gray matter in 803 participants from the Alzheimer's Disease Neuroimaging Initiative.

Authors:  Sarah K Madsen; Priya Rajagopalan; Shantanu H Joshi; Arthur W Toga; Paul M Thompson
Journal:  Neurobiol Aging       Date:  2014-08-30       Impact factor: 4.673

8.  Preclinical Comparison of the Amyloid-β Radioligands [(11)C]Pittsburgh compound B and [(18)F]florbetaben in Aged APPPS1-21 and BRI1-42 Mouse Models of Cerebral Amyloidosis.

Authors:  Ann-Marie Waldron; Jeroen Verhaeghe; Leonie wyffels; Mark Schmidt; Xavier Langlois; Annemie Van Der Linden; Sigrid Stroobants; Steven Staelens
Journal:  Mol Imaging Biol       Date:  2015-10       Impact factor: 3.488

9.  Longitudinal Partial Volume Correction in 2-[18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Studies of Alzheimer Disease.

Authors:  Charles B Malpas; Michael M Saling; Dennis Velakoulis; Patricia Desmond; Rodney J Hicks; Terence J OʼBrien
Journal:  J Comput Assist Tomogr       Date:  2015 Jul-Aug       Impact factor: 1.826

10.  Fine-granularity functional interaction signatures for characterization of brain conditions.

Authors:  Xintao Hu; Dajiang Zhu; Peili Lv; Kaiming Li; Junwei Han; Lihong Wang; Dinggang Shen; Lei Guo; Tianming Liu
Journal:  Neuroinformatics       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.